

Comprehensive phenotyping of 3q29 deletion syndrome: recommendations for clinical care

Rossana Sanchez Russo MD, Michael J. Gambello MD PhD, Melissa M. Murphy PhD, Katrina Aberizk, Emily Black MD, T. Lindsey Burrell PhD, Grace Carlock, Joseph F. Cubells MD PhD, Michael T. Epstein, Roberto Espana, Katrina Goines, Ryan Guest, Cheryl Klaiman, Sookyong Koh, Elizabeth Leslie, Longchuan Li, Derek Novacek PhD, Celine A. Saulnier, Esra Sefik, Sarah Schultz, Elaine Walker, Stormi White PhD, The Emory 3q29 Project, Jennifer Gladys Mulle MHS PhD*

Melissa M. Murphy

Department of Human Genetics, Emory University School of Medicine

T. Lindsey Burrell

Department of Pediatrics, Emory University School of Medicine

Marcus Autism Center, Children's Healthcare of Atlanta and Emory University School of Medicine

Joseph F. Cubells

Departments of Human Genetics and Psychiatry and Behavioral Science, Emory University School of Medicine

Michael T. Epstein

Department of Psychiatry and Behavioral Science, Emory University School of Medicine

Roberto España

Department of Psychology, Emory University

Michael J. Gambello

Department of Human Genetics, Emory University School of Medicine

Katrina Goines

Department of Psychology, Emory University

Cheryl Klaiman

Department of Pediatrics, Emory University School of Medicine

Marcus Autism Center, Children's Healthcare of Atlanta and Emory University School of Medicine

Sookyong Koh

Department of Pediatrics, Emory University School of Medicine

Rossana Sanchez Russo

Department of Human Genetics, Emory University School of Medicine

Celine A. Saulnier

Neurodevelopmental Assessment & Consulting Services

Department of Pediatrics, Emory University School of Medicine

Elaine Walker

Department of Psychology, Emory University

*Jennifer Gladys Mulle

Department of Human Genetics, Emory University School of Medicine

Department of Epidemiology, Rollins School of Public Health, Emory University

*Corresponding author

Whitehead 305M

615 Michael Street

Atlanta GA 30322

(404) 727-3042 (office)

jmulle@emory.edu

Abstract

Purpose: To understand the consequences of the 3q29 deletion on medical, neurodevelopmental, psychiatric, and neurological sequelae by systematic evaluation of affected individuals. To develop evidence-based recommendations using these data for effective clinical care.

Methods: 32 Individuals with the 3q29 deletion were evaluated using a defined phenotyping protocol and standardized data collection instruments.

Results: Medical manifestations were varied and reported across nearly every bodily system, with congenital heart defects (25%) the most severe and heterogeneous gastrointestinal symptoms (81%) the most common. Physical exam revealed a high proportion of musculoskeletal findings (81%). Neurodevelopmental phenotypes represent a significant burden and include intellectual disability (34%), autism spectrum disorder (38%), executive function deficits (46%), and graphomotor weakness (78%). Psychiatric illness manifests across the lifespan with schizophrenia prodrome (15%), psychosis (20%), anxiety disorders (40%) and ADHD (63%). On neurological exam study subjects displayed only mild or moderate motor difficulties.

Conclusions: By direct evaluation of 3q29 deletion study subjects, we document common features of the syndrome, including a high burden of neurodevelopmental and neuropsychiatric phenotypes. Evidence-based recommendations for evaluation, referral, and management are provided to help guide clinicians in the care of 3q29 deletion patients.

Keywords (up to 5):

3q29 deletion syndrome

Genomic disorder

Copy-number variant

Introduction

Individuals with 3q29 deletion syndrome (OMIM #609425) are hemizygous for a 1.6 Mb interval containing 21 protein coding genes¹. The syndrome has a prevalence of ~1 in 30,000 and is associated with reduced birth weight, failure to thrive, heart defects, intellectual disability, anxiety disorder, autism spectrum disorder, and schizophrenia¹⁻⁶. Case reports have provided a rich source of data on individual patients and have illuminated many facets of the syndrome^{2, 7-27}. However,

phenotyping in case reports is rarely systematically applied, leading to bias in the curation of associated signs and symptoms². Large cohorts of deidentified individuals referred for genetic testing²⁸⁻³¹ or ascertained for a specific phenotype (such as autism spectrum disorder³² or schizophrenia^{5, 33-35}) confirm the pathogenicity of the 3q29 deletion and provide evidence of increased risk for a single phenotype, but do not inform about the broader phenotypic spectrum. Systematic self-report of phenotypes from registries are also emerging, but are hampered by limitations of self-report data^{3, 4}. For these reasons a comprehensive, unbiased characterization of the syndrome is needed, using gold standard instruments and direct evaluation of study subjects by trained experts³⁶.

We sought to address these knowledge gaps in the clinical phenotype of 3q29 deletion syndrome. The Emory 3q29 Project unites an interdisciplinary team toward understanding the phenotypic spectrum, natural history, and molecular mechanisms of 3q29 deletion syndrome (<http://genome.emory.edu/3q29/>). As part of this project, our clinical team of investigators has directly and systematically evaluated 32 study subjects with the canonical 1.6 Mb 3q29 deletion using a standardized, transdiagnostic phenotyping protocol that includes gold-standard instruments³⁶. These data have revealed new aspects of 3q29 deletion syndrome and provide guidance for the medical geneticist on recommended referral, follow-up, and management of patients.

Materials and Methods

Study subject eligibility: The study design, eligibility, recruitment criteria, and evaluation process have been previously described³⁶. Briefly, individuals were recruited from the 3q29 registry housed at Emory University³ (3q29deletion.org). Inclusion criteria were: validated diagnosis of 3q29 deletion syndrome by documented chromosome microarray analysis where the deletion overlapped the canonical region (hg19, chr3:195725000-197350000) by $\geq 80\%$, and willingness and ability to travel to Atlanta GA. Exclusion criteria were: any 3q29 deletion with less than 80% overlap with the canonical region; non-fluency in English, and age younger than six years. One exception to the age criterion was made; a 4.85 year old who was part of a previously-described multiplex family was included in the study²⁷. After an informed consent session with a staff scientist (MM), travel was arranged. This study was approved by the Emory Institutional Board (IRB000088012). Participant characteristics are summarized in Table 1.

Evaluations: All study subjects were evaluated over two days at a designated clinical evaluation site. An in-person informed consent and assent procedure was repeated on the first study day. Evaluations were conducted as follows (summarized in Table 2):

Medical History & Physical Examination: Parents completed a comprehensive medical history (Supplementary Information), which was reviewed during the visit with a trained medical geneticist (EB, RSR, MJG). The medical geneticist also completed a physical examination of the study subject. Photographs were taken of the front and profile of the face and any other physical characteristics of note. When possible, medical records were obtained to validate significant medical concerns. Following the study visits, the medical geneticists met to discuss the results of the medical history and physical examination, identify relevant diagnoses by system, and classify each diagnosis using the Human Phenotype Ontology (HPO) terminology when available. HPO terminology provides a classification system for clinical abnormalities in humans (<https://hpo.jax.org/app/>). A detailed assessment of craniofacial characteristics was based upon physical examination notes and the photographs taken during the visit. Z-scores and percentiles for height, weight, and head circumference were determined according to *The Handbook of Physical Measurements*³⁷ and were generated using the Face2Gene application.

Neurodevelopmental Evaluation: Table 2 summarizes a systematic battery used to evaluate neurodevelopmental phenotypes, which included assessments of cognitive ability (Differential Ability Scales, 2nd ed.³⁸ (DAS) for ages <18; Wechsler Abbreviated Scale of Intelligence³⁹ (WASI) for ages ≥ 18), adaptive behavior (Vineland Adaptive Behavior Scales 3rd ed.⁴⁰), visual-motor integration (Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th ed.⁴¹ (VMI)), Autism spectrum disorder (Autism Diagnostic Interview, Revised⁴² (ADI-R); Autism Diagnostic Observation Schedule, 2nd ed.⁴³ (ADOS)), and executive function (Behavior Rating Inventory of Executive Functions⁴⁴ (BRIEF-2 for ages <18, BRIEF-A for ages ≥ 18)).

Cognitive testing, VMI, and autism assessments were carried out by clinical psychologists (CS, CK, SW) early in the day to reduce fatigue. The Vineland and BRIEFs were completed by the parent or caretaker electronically via the publisher websites (Pearson Q-global and PARiconnect, respectively) either before or during the visit.

Psychiatric Evaluation: A systematic battery was also used to assess anxiety (Anxiety Disorders Interview Schedule for Children^{45, 46} (ADIS) in ages <18, Structured Clinical Interview for DSM-V Diagnosis, Research Version⁴⁷ (SCID-5-RV) in ages 18+); general psychopathology (Schedule for Affective Disorders and Schizophrenia for School Aged Children⁴⁸ (KSADS) in ages <18, SCID-5-RV⁴⁷ in ages 18+); prodrome (Structured Interview for Prodromal symptoms^{49, 50} (SIPS)) and psychosis (SCID-5-RV). Prodrome and psychosis were evaluated in individuals age 8 years and older; at younger

ages, developmentally appropriate magical thinking cannot be distinguished from true psychosis. Anxiety disorders in study subjects < 18 were evaluated with the ADIS, administered by a trained clinician (TLB). The KSADS, SCID-5-RV, and SIPS were administered by clinical psychology trainees (RE, DN, KG, KA, RG) supervised by a team clinical psychologist (EW). A qualitative assessment of global mental status and health was conducted by team psychiatrists (JFC, ME) to supplement impression and results from the formal assessments.

Neurological Exam: A subset of study subjects (n = 23) were evaluated by a pediatric neurologist (SK) for gross and fine motor phenotypes, including assessment of gait, heel to toe and stressed gait, fine finger movements, rapid alternating movements, as well as finger to nose and heel to shin tests. Performance on each task was rated using a 4-point scale of impairment severity: 0 (none/normal), 1 (mild), 2 (moderate), and 3 (severe). General clinical impressions were also noted. Exam results were recorded using a semi-structured data collection template; after the study visit data were entered into redcap.

Results:

Participants: 32 participants were consented and evaluated, including 4 participants from a single family²⁷. Study subjects ranged in age from 4.8-39.1 years (mean age 14.5 years, median age 11.7 years); 62.5% (n = 20) were male. Study subjects were recruited from across the US, Canada, and the UK (Table 1).

Medical history results. A summary of symptoms and diagnoses that occurred in at least 10% of study subjects evaluated is presented in Table 3. Supplemental table 1 includes any symptoms or diagnosis reported in at least one study subject. The medical history review did not reveal any significant pre- or peri-natal findings that were generalizable across subjects.

Review of systems

Ear, nose, and throat (ENT): 78% of study subjects (n = 25) reported an ENT-related symptom or diagnosis in their medical history. 22% of subjects (n = 7) reported recurrent ear infections, and 3 required surgery. 59% (n = 19) had a symptom or diagnosis related to the eye. The most common ocular phenotype was strabismus (28%, n = 9), with 3 subjects requiring surgery. Vision problems encountered later in childhood included astigmatism (16%, n = 5) and myopia (16%, n = 5). Epistaxis was the most common nasal manifestation occurring in 22% of study subjects (n = 7), two of whom required surgical correction. Dental anomalies were reported in 41% (n = 13) and commonly included enamel hypoplasia with proclivity to caries and abnormalities in number and size of teeth.

Cardiovascular: Structural cardiovascular disease is reported in 47% (n = 15) of patients. These included complex congenital cardiovascular disease (25%, n = 8) such as hypoplastic right heart (n = 1), patent ductus arteriosus (n = 2), pulmonary atresia (n = 2), pulmonary stenosis (n = 1), tricuspid stenosis (n = 1), ventricular septal defect (n = 2), and arterial-venous malformation (AVM) originating from the descending thoracic aorta (n = 1). Four individuals in this study (12.5%) required surgery to address their cardiovascular condition.

Gastrointestinal: Gastrointestinal manifestations were noted in the majority (81%, n = 26) of patients. Among these, half of the patients (50%, n = 16) reported gastroesophageal reflux and 41% (n = 13) reported chronic constipation. Additionally, feeding difficulties in infancy were reported in more than half of patients (59%, n = 19) and persisted beyond infancy in 16% (n = 5). Only 9% (n = 3) of patients had failure to thrive in infancy, 2 of whom continued to have failure to thrive beyond infancy. In contrast, failure to thrive beyond infancy was reported in 41% (n = 13).

Renal/Genitourinary: Enuresis was encountered in 25% (n = 8) of our cohort. Of these, seven had ongoing enuresis. The remaining study subject had a history of enuresis reported by parents during the medical history interview that was resolved at the time of this study.

Respiratory, allergy, and immunological: Asthma was the most common respiratory manifestation, occurring in 19% (n = 6) of patients. Seasonal allergies were reported in 16% (n = 5) of subjects, two of whom also had asthma. Food allergies were noted in 13% (n = 4) of subject.

Integumentary: 13% (n = 4) of subjects reported a diagnosis of eczema. Keratosis pilaris was also reported in 13% (n = 4) of subjects.

Sleep: Sleep disturbances were reported in at least 31% (n = 10) with 28% (n = 9) reporting difficulty initiating or maintaining sleep, and 1 person reporting sleep walking.

Neurological: Seizures were reported in 13% (n = 4) of subjects. 16% (n = 5) of subjects reported experiencing headache or migraine.

Medical History and Physical examination. Table 4 presents a summary of review of systems and physical findings (symptoms are not found on PE but reported by the patient) and diagnoses in at least 10% of study subjects evaluated. Supplemental table 2 includes any symptoms or diagnosis found in at least one study subject.

Growth parameters. Compared to age and sex norms, 25% of subjects (n = 8) had a weight -2 SD below the mean. These subjects ranged from 4-24 years and were evenly split between males and females. 16% of subjects (n = 5) were -2 SD below the mean for height. These subjects were 4 males and 1 female ranging in age from 4-39 years. 16% (n = 5) were -2 SD below the mean for head circumference. These subjects were 4 males and 1 female ranging from 4-12 years old. No subject

had low weight, height, and head circumference. Most subjects had low measurements only in one parameter.

Dysmorphic features. Subtle craniofacial dysmorphisms were noted among patients in the nasal region. These findings were identified by medical geneticists during the physical exam and quantified through next generation phenotyping technology through Face2Gene (FDNA, Inc., Boston, MA). See Mak et al (manuscript in preparation) for additional information.

Musculoskeletal manifestations. On physical exam, 84% (n = 27) of study subjects had one or more musculoskeletal phenotypes. Chest deformities were noted in 41% (n = 13), and included pectus excavatum (25%, n = 8), pectus carinatum (9%, n = 3), and chest asymmetry (6%, n = 2). Manifestations in the upper extremities were seen in 47% of study subjects (n = 15). The most common findings were long, thin fingers (22%, n = 7) and tapered fingers (13%, n = 4). Lower extremity manifestations were seen in 72% of study subjects (n = 23). These included pes planus (31%, n = 10) or medial rotation of medial malleolus (31%, n = 10), with 22% having *both* pes planus and medial rotation of the medial malleolus. Abnormalities of the toes were also observed in 28% (n = 9) of study subjects, including abnormal hallux (13%, n = 4) commonly seen as broad hallux and hallux valgus, and abnormal non-hallux toes (19%, n = 6) frequently seen as curved, short, or overlapping toes.

Within the other systems examined, individual symptoms or diagnoses were noted (see Supplemental Table 2), but no single finding was frequent enough to be generalizable across study subjects.

Neurodevelopmental Phenotypes: Rates of neurodevelopmental and psychiatric diagnoses are shown in Figure 1; quantitative mean and median scores with ranges are shown in Table 5.

Cognitive Ability and Adaptive Function: Mean IQ score (FSIQ) was 73.0 (median 75.5, range 40-99). Mean adaptive function as measured with the Vineland was 73.9 (median 70.1, range 48-107). Individuals were considered to have intellectual disability if both GCA and adaptive behavior scores were >2 SD below the expected mean (> 70 on both evaluations), consistent with DSM-V criteria. By this metric, 11 individuals (34%) qualified for a diagnosis of ID.

Graphomotor Weakness: 78% of study subjects were found to have clinically significant graphomotor weakness, defined as a score < 2 SD below the expected mean. Examination of subtest scores indicated greater weakness in motor coordination than visual perception.

Executive Function: 47% of study subjects (n = 15) were found to have clinically significant deficits in Executive Function, with T-scores that were ≥ 2 SD above the mean.

Autism: Autism was assessed using the ADOS and ADI-R; these instruments were used to inform the administering clinician's best estimate diagnosis. Of 32 individuals evaluated, 12 (37.5%) met DSM-V criteria for a diagnosis of Autism Spectrum Disorder. Nine of 20 males evaluated (45%) qualified for a diagnosis of autism, a 19.5-fold excess as compared to the general population rate of 1 in 42 males (2.3%)⁵¹. Three out of 12 females evaluated (25%) also qualified for a diagnosis of autism, a 50-fold excess compared to the general population rate of ASD in females (1 in 189, 0.5%)⁵¹. These data confirm there is a high risk for autism associated with the 3q29 deletion in both males and females.

Psychiatric Evaluation:

Anxiety Disorders: 40% (n = 13) of study subjects qualified for at least one anxiety disorder; 18% (n=6) had more than one anxiety disorder diagnosis. Anxiety disorders included generalized anxiety disorder (22%, n = 7), specific phobia (19%, n = 6), separation anxiety (12.5%, n = 4) and social anxiety disorder (6%, n = 2).

Prodromal Symptoms & Psychosis: Of 21 individuals who were evaluated, 19% (n = 4) qualified for diagnosis of a psychotic disorder. Three additional individuals (14%) were found to exhibit features consistent with the schizophrenia prodrome. These data are consistent with prior reports establishing the 3q29 deletion as a risk factor for schizophrenia^{5, 6, 33-35}.

General Psychopathology: 63% (n = 20) of individuals evaluated qualified for a diagnosis of attention-deficit hyperactivity disorder (ADHD). 19 of these individuals could be further classified into subtypes: ADHD-inattentive type (n = 10), ADHD-combined type (n = 8), and ADHD- Hyperactive/impulsive (n = 1). One additional individual did not fit criteria for any subtype and was diagnosed as "other specified ADHD." The high rate of ADHD in 3q29 deletion study subjects is consistent with deficits in executive function, as reported above. No other psychiatric diagnosis was present in great than 10% of study subjects. Two people met criteria for intermittent explosive disorder; two people met criteria for obsessive compulsive disorder; two people met criteria for major depressive disorder. For each of the following diagnoses, one person met criteria: oppositional defiant disorder, conduct disorder, Bipolar I disorder.

Neurological Exam: A subset of study subjects (n = 23) were evaluated by a trained pediatric neurologist for motor phenotypes associated with cerebellar dysfunction. Motor phenotypes were

identified, but generally were mild (range 30-47%) or moderate (range 4-48%, Table 6). Only one person displayed a severe cerebellar motor phenotype, in rapid alternating movement.

Discussion

Here we report the first comprehensive description of 3q29 deletion syndrome, by direct systematic evaluation of 32 study subjects using a defined protocol and gold-standard instruments. While nearly all major systems are affected in 3q29 deletion syndrome, the ocular, dental, cardiovascular, gastrointestinal, renal, musculoskeletal and neurologic systems are affected with the greatest frequency and should be prioritized for evaluation and follow-up. There is also a high burden of neurodevelopmental and neuropsychiatric illness, requiring intervention and support across the lifespan. Our findings motivate recommendations for clinical care, described in detail below and summarized in Table 7.

Almost 60% of subjects reported ocular manifestations, the most frequently occurring ocular manifestations were strabismus and refractive errors, including myopia and astigmatism. In some cases, the strabismus required surgical repair. The high rate of ocular manifestations is consistent with previous reports² and suggests the importance of involving a pediatric ophthalmologist at time of diagnosis for standard treatment of refractive errors and strabismus.

Similar to prior reports^{2,3,7}, recurrent ear infections were common among study subjects and sometimes required myringotomy tubes. Epistaxis has not been previously reported but was commonly seen in a little over 20% of subjects without a concurrent history of nose picking. Two of the seven cases required surgery, one of which had developed anemia. The high rates of ear infections and epistaxis suggest a low threshold for involving ENT in care. When taken together with increased risk for speech-language disorders, these results further highlight the importance of hearing screening to monitor for conductive hearing loss and associated disruptions to speech-language development.

Consistent with reports of dental anomalies in the literature^{2,3,7}, parents of 41% of subjects in our study reported a broad spectrum of dental anomalies, such as abnormal tooth shape, size, and number, diastema, enamel hypoplasia, and frequent cavities. In some cases, extensive surgical intervention was required, including up to 5 root canals in a single individual. Cavities occurred despite parent reported good oral hygiene. Notably, our study and others^{2,3,16} report dental anomalies along with gastroesophageal reflux, which may contribute to dental problems. Regardless, the high frequency of dental problems among individuals with 3q29 deletion highlights the need for early and ongoing dental care by a pediatric dentist, which may include increased frequency of routine check-ups and cleanings along with education in dental hygiene.

Previous literature draws attention to elevated rates of heart defects in individuals with 3q29 deletion^{2, 3, 16}. Our findings confirm this increased risk. Structural cardiovascular manifestations were reported in almost half of subjects. Almost all manifestations were heart defects ranging in severity from PDA to hypoplastic right heart syndrome. No single common congenital heart defect was observed. One subject had a large AVM originating from the descending aorta, which was incidentally found on imaging for back pain. Of note, however, is that this subject also had an additional loss of 188 kb in 7q31.31 of uncertain significance that included only 1 OMIM gene, *KCND2*. To date AVMs have not typically been associated with *KCND2* or described in 3q29, thus it is unclear whether this AVM is related to 3q29. Additional genetic testing was not performed. Regardless, it is important to note that half of subjects with a cardiovascular manifestation required surgical repair, suggesting the need for echocardiogram at diagnosis, if not previously done.

Gastrointestinal manifestations occurred in 81% of subjects and are noted as early as infancy. Feeding difficulties in infancy, manifesting as problems with latching to the breast and sucking, were sometimes associated with failure to gain weight and were common presenting signs. Feeding difficulties, coupled with reflux and constipation, and less frequently, dysphagia and esophageal dysmotility, persisted beyond infancy. Three subjects needed gastrostomy tubes beyond infancy due to restrictive food preferences and failure to thrive. It is unclear how much feeding problems may contribute to the observed smaller height and lower weight as documented in growth parameters (discussed subsequently) and/or whether these subjects are constitutionally smaller.

Occurring in 22% of subjects, enuresis was the most common renal/genitourinary manifestation reported. The subjects with a diagnosis of enuresis ranged in age from 6 to 16.9 years, suggesting that enuresis continues beyond the age in which it often resolves spontaneously. Enuresis is typically diagnosed more commonly among males than females in the general population. However, this sex difference was not apparent among our subjects, 4 of whom were male and 3 of whom were female, which supports the notion that the 3q29 deletion contributes to enuresis. Indeed, prior case studies report a 15-year-old male² and an 8-year-old female¹³ with urinary voiding dysfunction. Although varied by age and gender, the frequency of enuresis is reported to be 2.8% for children ages 6-14 years in the general population, indicating an approximately 9-fold enrichment among our study subjects and may require behavioral or pharmacological intervention.

A constellation of respiratory, allergy, and immunological symptoms were reported among study subjects. We observed 19% of our study subjects had asthma, 16% had seasonal allergies, and 13% had food allergies. The rate of asthma and food allergies are higher than the rates reported in the general population^{52, 53}. Although the rates of seasonal allergy did not exceed the rate of 10-20% in the general population⁵⁴, these results taken together suggest a tendency to atopy. Moreover, common skin manifestations reported among study subjects included eczema and keratosis pilaris,

both of which are also associated with atopy. Early evaluation and routine follow-up with a pediatric pulmonologist or allergist may be important for ongoing care.

Although not previously reported in the literature, sleep disturbances were reported in 31% of subjects and ranged from difficulty initiating or maintaining sleep to reporting sleep walking and sleep apnea. Sleep disturbances can co-occur with other diagnoses, such as enuresis⁵⁵. Interestingly, half of the subjects in our cohort with enuresis also had a sleep disturbance. Diagnosis and management of sleep disorders, particularly among subjects with other co-morbidities, may lead to improvement in multiple areas.

Based upon growth parameters, preliminary analyses were conducted to explore the effect of sex and age on height and weight. Results for height and weight suggest there may be a sex by age interaction. Male children are only slightly shorter than the mean, but by adulthood are shorter as compared to the mean than they were as children. In contrast, females move in the opposite direction: they are short as children but move to the population average as adults. In adulthood, males with 3q29 deletion are shorter (relative to expectations) than females (p value 0.01). At young ages, females weight less than expected but catch up in adulthood. Males move in the opposite direction: They are closer to the mean as children and by adulthood weigh less than expected. Only an age effect was noted for head circumference. Children with 3q29 deletion (males and females) have an FOC that is well below the population mean, but by adulthood this effect is ameliorated.

There is a substantial burden of disability contributed by neurodevelopmental and psychiatric manifestations. Cognitive disability is present but mild to moderate in most of the study subjects we evaluated. However, there is likely a cumulative impact of diminished cognitive ability alongside multiple comorbidities, including autism spectrum disorder, executive function deficits, anxiety disorders, and ADHD, that impair functioning and are a threat to successful social and occupational functioning. The high rate of graphomotor weakness indicates that writing and other fine motor tasks may be effortful and introduce challenges in academic settings. Occupational therapy may be helpful. Creative classroom solutions to alleviate the burden of writing tasks may decrease stress in these settings.

The high rate of ADHD, anxiety disorders, and schizophrenia/psychosis indicate that a child/adolescent psychiatrist should be part of the medical team, with periodic evaluation throughout development to detect emerging symptoms. Early intervention with cognitive behavioral therapy may be effective for anxiety disorders. Anxiety disorders, ADHD, and psychosis may require control with pharmaceutical agents. Because of the risk of psychosis associated with the 3q29 deletion, it is recommended that stimulant use for ADHD treatment be avoided if possible.

Limitations of this study include the small sample size, though we note that 32 study subjects is a relatively large sample size given the low frequency (1 in 30,000) of 3q29 deletion syndrome. However, this sample size allows us to describe only the most common manifestations of the syndrome; a larger sample size may reveal lower frequency symptoms. Because our study required travel to Atlanta GA, this may have introduced some ascertainment bias toward subjects who were healthy enough to travel; subjects with behavioral challenges may not have participated. Because this sample is relatively young (average age 14.5 years) we have limited ability to describe later onset symptoms of the syndrome. Future directions will include a larger sample size and longitudinal evaluation.

In conclusion, many of the medical, neurodevelopmental, and psychiatric findings, although frequent, are nonspecific. Many symptoms noted require medical intervention, but do not necessarily signal the need for genetic testing. As a result, in individuals with 3q29 deletion syndrome, the need for genetic testing may be easily overlooked in the absence of other major congenital anomalies, thus getting to diagnosis remains a challenge. Taking into account the whole constellation of symptoms, including developmental and neuropsychiatric manifestations, are necessary to ensure patient access to genetic testing. Once 3q29 deletion syndrome is diagnosed, the findings and recommendations in the current study provide clinicians and families a road map toward effective strategies for care and treatment for individuals with 3q29 deletion syndrome.

Acknowledgements:

3q29 project members

NIH grants R01 MH110701 and R01 MH118534.

The 3q29 community

The Marcus Autism Center

Please note that any publication that results from a project utilizing REDCap should cite grant support (UL1 TR000424))

Table 1: Study Subjects	
Sex	
Male	20 (63%)
Female	12 (37%)
Age - Mean (SD)	14.5 (8.26) years
Age - Range	4.85-39.12 years
Ethnicity (% non-Hispanic)	31 (97%)
Race	
White	29 (91%)
More than 1 race	3 (9%)

Table 2: Assessments and measures used in this study

Evaluation	Domain & Measures
Medical	<p>Medical History</p> <ul style="list-style-type: none"> • Patient medical history by organ system • Family medical history • Family pedigree <p>Physical Examination</p> <ul style="list-style-type: none"> • Anthropomorphic Measures • Physical examination by organ system • Growth parameters (e.g., height, weight, head circumference)
Neurodevelopmental	<p>Autism</p> <ul style="list-style-type: none"> • <i>Autism Diagnostic Interview -Revised</i> (ADI-R) • <i>Autism Diagnostic Observation Schedule, 2nd ed</i> (ADOS-2) <p>Cognitive Ability & Adaptive Function</p> <ul style="list-style-type: none"> • Differential Abilities Scale, 2nd ed (DAS-II)^a • Beery-Buktenica Visual Motor Integration Test-6th ed (VMI-6) • <i>Behavioral Rating Inventory of Executive Functions, 2nd ed</i> (BRIEF-2)^a and Adult version (BRIEF-A)^b • Vineland Adaptive Behavior Scales, 3rd ed, Parent/Caregiver Interview Form • Wechsler Abbreviated Scale of Intelligence, 2nd ed (WASI-II)^b
Psychiatric	<p>Anxiety</p> <ul style="list-style-type: none"> • <i>Anxiety Disorders Interview Schedule for DSM –IV (ADIS-IV) Child Version</i>^a • <i>Structured Clinical Interview for DSM-V --Research Version</i> (SCID-5-RV) - Module F^{b, c} <p>Prodromal Symptoms & Psychosis</p> <ul style="list-style-type: none"> • Scheduled Interview for Prodromal Symptoms (SIPS) • <i>Structured Clinical Interview for DSM-V --Research Version</i> (SCID-5-RV) - Module B/C^b <p>General Psychopathology</p> <ul style="list-style-type: none"> • <i>Kiddie Schedule for Affective Disorders and Schizophrenia</i> (K-SADS)^{a, c} • <i>Structured Clinical Interview for DSM-V --Research Version</i> (SCID-5-RV) - Modules A, D, G, H, I, K^b
Neurological	Gross and fine motor skill assessment

^a Administered to ages 6-18 years, ^b administered to ages 19+ years, ^c For some cases ages 19-22 years, the K-SADS was used to assess anxiety and psychopathology.

Table 3: Frequency of symptoms and diagnoses reported in 10% or more of participants (N = 32)

Symptoms/Diagnoses with Associated Procedure or	n	%
---	---	---

Intervention		
General	7	22%
Fatigue	7	22%
HEENT	25	78%
Recurrent Infection addressed with surgery (any)	6	-
<i>Cases requiring tonsillectomy</i>	4	-
<i>Cases requiring adenoidectomy</i>	5	-
Eye (any)	19	59%
Astigmatism	5	16%
Myopia	5	16%
Strabismus	9	28%
<i>Cases with strabismus requiring surgery</i>	3	-
Ear (any)	7	22%
Recurrent ear infection	7	22%
<i>Cases requiring myringotomy and tube placement</i>	3	-
Nose (any)	8	25%
Epistaxis	7	22%
<i>Cases with epistaxis requiring surgery</i>	2	-
Teeth (any)	13	41%
Abnormal Number or Size of Teeth	5	16%
Abnormal Dentition	9	28%
Cardiovascular	16	50%
Structural	15	47%
Murmur	7	22%
Complex congenital cardiovascular disease	8	25%
<i>Cases requiring surgery</i>	4	-
Respiratory	8	25%
Asthma	6	19%
Sleep	10	31%
Sleep Disturbance	9	28%
Gastrointestinal	26	81%
Feeding Problems Beyond Infancy	5	16%
Failure to Thrive Beyond Infancy	13	41%
Constipation	13	41%
Reflux	16	50%
Feeding Problems in Infancy	19	59%
Renal/Genitourinary	9	28%
Enuresis	7	22%
Integumentary/Dermatologic	11	34%
Eczema	4	13%
Keratosis Pilaris	4	13%
Allergy/immunology	9	28%
Food Allergy	4	13%
Seasonal Allergies	5	16%
Neurological (any)	18	56%
Seizures (e.g., atonic, febrile, nocturnal)	4	13%
Headache or Migraine	5	16%

Table 4. Frequency of Physical Exam Findings documented in 10% or more of participants

Finding	n	%
Musculoskeletal (any)	27	84%
Axial (any)	15	47%

Chest deformities (e.g., chest asymmetry, pectus carinatum, pectus excavatum)	13	41%
Extremity – Upper (any)	15	47%
Tapered Finger	4	13%
Long, Thin Finger	7	22%
Extremity – Lower (any)	23	72%
Abnormal Toes (e.g., hallux valgus, big or broad hallux, overlapping or curved toes)	9	28%
Medial Rotation Medial Malleolus	10	31%
Pes Planus	10	31%

Note. Numbers in bold face type represent a count of any instance in the category for each case (total possible = 32).

Table 5. Mean and median scores on neurodevelopmental instruments

Domain	Mean	Median	Range
Cognitive, standard score (GCA or FSIQ)	73.0	75.5	99-40
Adaptive behavior, standard score	73.9	70.5	48-110
Executive Function, T-score	68.3	69.0	45-88
Visual Motor Integration, standard score	69.5	67	45-103

Standard Scores have an expected population mean of 100 and a standard deviation of 15; scores *below* 70 (2 SD from the expected mean) are considered to denote a clinically significant weakness. *T-scores* have an expected population mean of 50 and a standard deviation of 10; scores *above* 70 (2 SD from the expected mean) are considered to denote a clinically significant weakness.

Table 6: Results of Neurological Exam for 23 individuals with 3q29 deletion syndrome

	Fine Finger Movement	Rapid Alternating Movement	Heel to Shin Task	Finger to Nose Task	Tandem Walk
normal/score 0 (%)	6 (26%)	4 (17%)	6 (32%)	14 (61%)	11 (55%)
Mild/score 1 (%)	9 (39%)	7 (30%)	9 (47%)	8 (35%)	6 (30%)
moderate/score 2 (%)	8 (35%)	11 (48%)	4 (21%)	1 (4%)	3 (15%)
severe/score 3 (%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)
not normal (%)	17 (74%)	19 (83%)	13 (68%)	9 (39%)	9 (45%)

Table 7: Recommendations for clinical care for individuals with 3q29 deletion syndrome

System	Evaluation	When	Recommendations
Ocular	Follow up with ophthalmologist	At diagnosis	<ul style="list-style-type: none"> • Vision screening to monitor for refractive errors and strabismus • Strabismus may require patching or surgery
Ears, Nose, Throat	Follow up with otolaryngology (ENT)	As needed	<ul style="list-style-type: none"> • Hearing screening • Monitoring recurrent ear infections and epistaxis • Standard surgical management as required
Dental	Ongoing follow up with dentist for abnormal enamel, tooth shape, and number	Ongoing	<ul style="list-style-type: none"> • Initial pediatric dental evaluation by 1 year of age • May need increased frequency of check-ups and cleanings • Dental care may require assistance with daily brushing and flossing
Cardiovascular	Evaluation by cardiologist	At diagnosis	<ul style="list-style-type: none"> • Echocardiogram • Evaluation in infancy or at diagnosis for evidence of congenital cardiovascular disease
Gastrointestinal	Consider referral to gastroenterologist and/or feeding specialist or nutritionist	As needed	<ul style="list-style-type: none"> • Consider evaluation for feeding and growth as indicated • Behavioral and/or medical treatment of constipation, if persistent • Age-specific treatment for reflux, including testing for food allergies
Renal	Follow up with urologist	As needed	<ul style="list-style-type: none"> • Consider evaluation for enuresis, if persistent • Consider behavioral interventions, including alarm techniques, if indicated • May require evaluation of medications that could contribute to enuresis
Musculoskeletal	Referral to orthopedist as needed	As needed	<ul style="list-style-type: none"> • Evaluation for chest anomalies and flat feet • Routine screening for scoliosis
Pulmonary and Sleep	Referral to pulmonologist/sleep clinic, as needed	As needed	<ul style="list-style-type: none"> • Sleep study, as needed • Recommendations for implementing healthy sleep hygiene habits • Management of sleep disturbance, as needed
Allergy and Immunology	Referral to specialist as needed	As needed	<ul style="list-style-type: none"> • Allergy testing, as needed • Standard management for asthma, allergies, and eczema • Assess for food allergies
Neurological	Referral to neurologist and/or developmental	At diagnosis and ongoing	<ul style="list-style-type: none"> • Evaluation for seizures, if indicated • Evaluation for developmental needs and early

	pediatrician, as needed		<p>intervention (e.g., occupational, physical, and speech-language therapy)</p> <ul style="list-style-type: none"> Evaluation of fine motor function and intervention (occupational therapy)
Neurodevelopmental	Referral to clinical psychologist	Follow-up throughout early childhood	<ul style="list-style-type: none"> Evaluation for autism spectrum disorder, cognitive ability, executive function deficits Evaluation for developmental needs and early intervention (e.g., speech-language therapy, cognitive behavioral therapy for social skills training) Adaptive behavior (skills training)
Psychiatric	Referral to child/adult psychiatrist	Childhood to early adult	<ul style="list-style-type: none"> Periodic evaluation for anxiety disorders, attention-deficit hyperactivity disorder, emerging features of prodrome/psychosis Cognitive behavioral therapy for anxiety Medications for anxiety, ADHD, psychosis may be indicated




Figure 1: Percent of 3q29 deletion participants who qualify for neurodevelopmental and neuropsychiatric diagnoses after direct evaluation by our team. 19% of study subjects qualified for a diagnosis of psychosis; 15% had features of schizophrenia prodrome (light blue). ID, intellectual disability; ASD, autism spectrum disorder; ADHD, attention-deficit hyperactivity disorder; VMI, visual-motor integration.

References

1. Mulle JG, Gambello MJ, Cook EH, Rutkowski TP, Glassford M. 3q29 Recurrent Deletion. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews(R). Seattle (WA)1993.
2. Cox DM, Butler MG. A clinical case report and literature review of the 3q29 microdeletion syndrome. *Clinical dysmorphology*. 2015;24(3):89-94. Epub 2015/02/26. doi: 10.1097/MCD.0000000000000077. PubMed PMID: 25714563.
3. Glassford MR, Rosenfeld JA, Freedman AA, Zwick ME, Mulle JG, Unique Rare Chromosome Disorder Support G. Novel features of 3q29 deletion syndrome: Results from the 3q29 registry. *American journal of medical genetics Part A*. 2016;170(4):999-1006. doi: 10.1002/ajmg.a.37537. PubMed PMID: 26738761.

4. Pollak RM, Murphy MM, Epstein MP, Zwick ME, Klaiman C, Saulnier CA, Emory 3q P, Mulle JG. Neuropsychiatric phenotypes and a distinct constellation of ASD features in 3q29 deletion syndrome: results from the 3q29 registry. *Mol Autism*. 2019;10:30. Epub 2019/07/28. doi: 10.1186/s13229-019-0281-5. PubMed PMID: 31346402; PMCID: PMC6636128.
5. Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, Antaki D, Shetty A, Holmans PA, Pinto D, Gujral M, Brandler WM, Malhotra D, Wang Z, Fajardo KVF, Maile MS, Ripke S, Agartz I, Albus M, Alexander M, Amin F, Atkins J, Bacanu SA, Belliveau RA, Jr., Bergen SE, Bertalan M, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Bulik-Sullivan B, Byerley W, Cahn W, Cai G, Cairns MJ, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Cheng W, Cloninger CR, Cohen D, Cormican P, Craddock N, Crespo-Facorro B, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, Del Favero J, DeLisi LE, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farh KH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedman JI, Forstner AJ, Fromer M, Genovese G, Georgieva L, Gershon ES, Giegling I, Giusti-Rodriguez P, Godard S, Goldstein JI, Gratten J, de Haan L, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Huang H, Ikeda M, Joa I, Kahler AK, Kahn RS, Kalaydjieva L, Karjalainen J, Kavanagh D, Keller MC, Kelly BJ, Kennedy JL, Kim Y, Knowles JA, Konte B, Laurent C, Lee P, Lee SH, Legge SE, Lerer B, Levy DL, Liang KY, Lieberman J, Lonqvist J, Loughland CM, Magnusson PKE, Maher BS, Maier W, Mallet J, Mattheisen M, Mattingdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melle I, Meshulam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Muller-Myhsok B, Murphy KC, Murray RM, Myin-Germeys I, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, Oh SY, Olincy A, Olsen L, O'Neill FA, Van Os J, Pantelis C, Papadimitriou GN, Parkhomenko E, Pato MT, Paunio T, Psychosis Endophenotypes International C, Perkins DO, Pers TH, Pietilainen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quedsted D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Savitz A, Schall U, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Silverman JM, Smoller JW, Soderman E, Spencer CCA, Stahl EA, Strengman E, Strohmaier J, Stroup TS, Suvisaari J, Svrakic DM, Szatkiewicz JP, Thirumalai S, Tooney PA, Veijola J, Visscher PM, Waddington J, Walsh D, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wormley BK, Wray NR, Wu JQ, Zai CC, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Cichon S, Collier DA, Corvin A, Daly MJ, Darvasi A, Domenici E, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jonsson EG, Kendler KS, Kirov G, Knight J, Levinson DF, Li QS, McCarroll SA, McQuillin A, Moran JL, Mowry BJ, Nothen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sklar P, St Clair D, Walters JTR, Werge T, Sullivan PF, O'Donovan MC, Scherer SW, Neale BM, Sebat J, Cnv, Schizophrenia Working Groups of the Psychiatric Genomics C. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nature genetics*. 2017;49(1):27-35. Epub 2016/11/22. doi: 10.1038/ng.3725. PubMed PMID: 27869829; PMCID: PMC5737772.
6. Mulle JG. The 3q29 deletion confers >40-fold increase in risk for schizophrenia. *Molecular psychiatry*. 2015;20(9):1028-9. Epub 2015/06/10. doi: 10.1038/mp.2015.76. PubMed PMID: 26055425; PMCID: 4546529.
7. Ballif BC, Theisen A, Coppinger J, Gowans GC, Hersh JH, Madan-Khetarpal S, Schmidt KR, Tervo R, Escobar LF, Friedrich CA, McDonald M, Campbell L, Ming JE, Zackai EH, Bejjani BA, Shaffer LG. Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication. *Molecular cytogenetics*. 2008;1:8. Epub 2008/05/13. doi: 10.1186/1755-8166-1-8. PubMed PMID: 18471269; PMCID: 2408925.
8. Willatt L, Cox J, Barber J, Cabanas ED, Collins A, Donnai D, FitzPatrick DR, Maher E, Martin H, Parnau J, Pindar L, Ramsay J, Shaw-Smith C, Sistiernans EA, Tettenborn M, Trump D, de Vries BB, Walker K, Raymond FL. 3q29 microdeletion syndrome: clinical and molecular characterization of

- a new syndrome. *American journal of human genetics*. 2005;77(1):154-60. Epub 2005/05/27. doi: 10.1086/431653. PubMed PMID: 15918153; PMCID: 1226188.
9. Cobb W, Anderson A, Turner C, Hoffman RD, Schonberg S, Levin SW. 1.3 Mb de novo deletion in chromosome band 3q29 associated with normal intelligence in a child. *Eur J Med Genet*. 2010;53(6):415-8. Epub 2010/09/14. doi: 10.1016/j.ejmg.2010.08.009. PubMed PMID: 20832509.
 10. Baynam G, Goldblatt J, Townshend S. A case of 3q29 microdeletion with novel features and a review of cytogenetically visible terminal 3q deletions. *Clin Dysmorphol*. 2006;15(3):145-8. Epub 2006/06/09. doi: 10.1097/01.mcd.0000198934.55071.ee. PubMed PMID: 16760732.
 11. Citta S, Buono S, Greco D, Barone C, Alfei E, Bulgheroni S, Usilla A, Pantaleoni C, Romano C. 3q29 microdeletion syndrome: Cognitive and behavioral phenotype in four patients. *Am J Med Genet A*. 2013;161A(12):3018-22. Epub 2013/11/12. doi: 10.1002/ajmg.a.36142. PubMed PMID: 24214349.
 12. Clayton-Smith J, Giblin C, Smith RA, Dunn C, Willatt L. Familial 3q29 microdeletion syndrome providing further evidence of involvement of the 3q29 region in bipolar disorder. *Clin Dysmorphol*. 2010;19(3):128-32. Epub 2010/05/11. doi: 10.1097/MCD.0b013e32833a1e3c. PubMed PMID: 20453639.
 13. Dasouki MJ, Lushington GH, Hovanes K, Casey J, Gorre M. The 3q29 microdeletion syndrome: report of three new unrelated patients and in silico "RNA binding" analysis of the 3q29 region. *Am J Med Genet A*. 2011;155A(7):1654-60. Epub 2011/06/01. doi: 10.1002/ajmg.a.34080. PubMed PMID: 21626679; PMCID: PMC3312009.
 14. Digilio MC, Bernardini L, Mingarelli R, Capolino R, Capalbo A, Giuffrida MG, Versacci P, Novelli A, Dallapiccola B. 3q29 Microdeletion: a mental retardation disorder unassociated with a recognizable phenotype in two mother-daughter pairs. *Am J Med Genet A*. 2009;149A(8):1777-81. Epub 2009/07/18. doi: 10.1002/ajmg.a.32965. PubMed PMID: 19610115.
 15. Khan WA, Cohen N, Scott SA, Pereira EM. Familial inheritance of the 3q29 microdeletion syndrome: case report and review. *BMC Med Genomics*. 2019;12(1):51. Epub 2019/03/20. doi: 10.1186/s12920-019-0497-4. PubMed PMID: 30885185; PMCID: PMC6421695.
 16. Li F, Lisi EC, Wohler ES, Hamosh A, Batista DA. 3q29 interstitial microdeletion syndrome: an inherited case associated with cardiac defect and normal cognition. *Eur J Med Genet*. 2009;52(5):349-52. Epub 2009/05/23. doi: 10.1016/j.ejmg.2009.05.001. PubMed PMID: 19460468.
 17. Monfort S, Rosello M, Orellana C, Oltra S, Blesa D, Kok K, Ferrer I, Cigudosa JC, Martinez F. Detection of known and novel genomic rearrangements by array based comparative genomic hybridisation: deletion of ZNF533 and duplication of CHARGE syndrome genes. *J Med Genet*. 2008;45(7):432-7. Epub 2008/04/17. doi: 10.1136/jmg.2008.057596. PubMed PMID: 18413373.
 18. Petrin AL, Daack-Hirsch S, L'Heureux J, Murray JC. A case of 3q29 microdeletion syndrome involving oral cleft inherited from a nonaffected mosaic parent: molecular analysis and ethical implications. *Cleft Palate Craniofac J*. 2011;48(2):222-30. Epub 2010/05/27. doi: 10.1597/09-149. PubMed PMID: 20500065; PMCID: PMC2964377.
 19. Quintero-Rivera F, Sharifi-Hannauer P, Martinez-Agosto JA. Autistic and psychiatric findings associated with the 3q29 microdeletion syndrome: case report and review. *American journal of medical genetics Part A*. 2010;152A(10):2459-67. Epub 2010/09/11. doi: 10.1002/ajmg.a.33573. PubMed PMID: 20830797.
 20. Sagar A, Bishop JR, Tessman DC, Guter S, Martin CL, Cook EH. Co-occurrence of autism, childhood psychosis, and intellectual disability associated with a de novo 3q29 microdeletion. *American journal of medical genetics Part A*. 2013;161A(4):845-9. Epub 2013/02/28. doi: 10.1002/ajmg.a.35754. PubMed PMID: 23443968; PMCID: 3685481.
 21. Tyshchenko N, Hackmann K, Gerlach EM, Neuhann T, Schrock E, Tinschert S. 1.6Mb deletion in chromosome band 3q29 associated with eye abnormalities. *Eur J Med Genet*. 2009;52(2-3):128-30. Epub 2009/03/21. doi: 10.1016/j.ejmg.2009.03.002. PubMed PMID: 19298871.
 22. Rossi E, Piccini F, Zollino M, Neri G, Caselli D, Tenconi R, Castellani C, Carrozzo R, Danesino C, Zuffardi O, Ragusa A, Castiglia L, Galesi O, Greco D, Romano C, Pierluigi M, Perfumo C, Di Rocco M, Faravelli F, Dagna Bricarelli F, Bonaglia M, Bedeschi M, Borgatti R. Cryptic telomeric

- rearrangements in subjects with mental retardation associated with dysmorphism and congenital malformations. *J Med Genet.* 2001;38(6):417-20. Epub 2001/06/27. doi: 10.1136/jmg.38.6.417. PubMed PMID: 11424927; PMCID: PMC1734891.
23. Koolen DA, Nillesen WM, Versteeg MH, Merckx GF, Knoers NV, Kets M, Vermeer S, van Ravenswaaij CM, de Kovel CG, Brunner HG, Smeets D, de Vries BB, Sistermans EA. Screening for subtelomeric rearrangements in 210 patients with unexplained mental retardation using multiplex ligation dependent probe amplification (MLPA). *J Med Genet.* 2004;41(12):892-9. Epub 2004/12/14. doi: 10.1136/jmg.2004.023671. PubMed PMID: 15591274; PMCID: PMC1735655.
24. Krepischi-Santos AC, Vianna-Morgante AM, Jehes FS, Passos-Bueno MR, Knijnenburg J, Szuhai K, Sloos W, Mazzeu JF, Kok F, Cherokee C, Otto PA, Mingroni-Netto RC, Varela M, Koiffmann C, Kim CA, Bertola DR, Pearson PL, Rosenberg C. Whole-genome array-CGH screening in undiagnosed syndromic patients: old syndromes revisited and new alterations. *Cytogenet Genome Res.* 2006;115(3-4):254-61. Epub 2006/11/25. doi: 10.1159/000095922. PubMed PMID: 17124408.
25. Malt EA, Juhasz K, Frengen A, Wangensteen T, Emilsen NM, Hansen B, Agafonov O, Nilsen HL. Neuropsychiatric phenotype in relation to gene variants in the hemizygous allele in 3q29 deletion carriers: A case series. *Mol Genet Genomic Med.* 2019;7(9):e889. Epub 2019/07/28. doi: 10.1002/mgg3.889. PubMed PMID: 31347308; PMCID: PMC6732294.
26. Shao L, Shaw CA, Lu XY, Sahoo T, Bacino CA, Lalani SR, Stankiewicz P, Yatsenko SA, Li Y, Neill S, Pursley AN, Chinault AC, Patel A, Beaudet AL, Lupski JR, Cheung SW. Identification of chromosome abnormalities in subtelomeric regions by microarray analysis: a study of 5,380 cases. *Am J Med Genet A.* 2008;146A(17):2242-51. Epub 2008/07/30. doi: 10.1002/ajmg.a.32399. PubMed PMID: 18663743; PMCID: PMC2680131.
27. Murphy MM, Burrell TL, Cubells JF, Epstein MT, Espana R, Gambello MJ, Goines K, Klaiman C, Koh S, Russo RS, Saulnier CA, Walker E, Emory 3q P, Mulle JG. Comprehensive phenotyping of neuropsychiatric traits in a multiplex 3q29 deletion family: a case report. *BMC Psychiatry.* 2020;20(1):184. Epub 2020/04/24. doi: 10.1186/s12888-020-02598-w. PubMed PMID: 32321479.
28. Coe BP, Stessman HAF, Sulovari A, Geisheker MR, Bakken TE, Lake AM, Dougherty JD, Lein ES, Hormozdiari F, Bernier RA, Eichler EE. Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. *Nature genetics.* 2019;51(1):106-16. Epub 2018/12/19. doi: 10.1038/s41588-018-0288-4. PubMed PMID: 30559488; PMCID: PMC6309590.
29. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, Williams C, Stalker H, Hamid R, Hannig V, Abdel-Hamid H, Bader P, McCracken E, Niyazov D, Leppig K, Thiese H, Hummel M, Alexander N, Gorski J, Kussmann J, Shashi V, Johnson K, Rehder C, Ballif BC, Shaffer LG, Eichler EE. A copy number variation morbidity map of developmental delay. *Nature genetics.* 2011;43(9):838-46. Epub 2011/08/16. doi: 10.1038/ng.909. PubMed PMID: 21841781; PMCID: PMC3171215.
30. Girirajan S, Rosenfeld JA, Coe BP, Parikh S, Friedman N, Goldstein A, Filipink RA, McConnell JS, Angle B, Meschino WS, Nezarati MM, Asamoah A, Jackson KE, Gowans GC, Martin JA, Carmany EP, Stockton DW, Schnur RE, Penney LS, Martin DM, Raskin S, Leppig K, Thiese H, Smith R, Aberg E, Niyazov DM, Escobar LF, El-Khechen D, Johnson KD, Lebel RR, Siefkas K, Ball S, Shur N, McGuire M, Brasington CK, Spence JE, Martin LS, Clericuzio C, Ballif BC, Shaffer LG, Eichler EE. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. *N Engl J Med.* 2012;367(14):1321-31. Epub 2012/09/14. doi: 10.1056/NEJMoa1200395. PubMed PMID: 22970919; PMCID: PMC3494411.
31. Kaminsky EB, Kaul V, Paschall J, Church DM, Bunke B, Kunig D, Moreno-De-Luca D, Moreno-De-Luca A, Mulle JG, Warren ST, Richard G, Compton JG, Fuller AE, Gliem TJ, Huang S, Collinson MN, Beal SJ, Ackley T, Pickering DL, Golden DM, Aston E, Whitby H, Shetty S, Rossi MR, Rudd MK, South ST, Brothman AR, Sanger WG, Iyer RK, Crolla JA, Thorland EC, Aradhya S, Ledbetter DH, Martin CL. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. *Genet Med.* 2011;13(9):777-84. Epub 2011/08/17. doi: 10.1097/GIM.0b013e31822c79f9. PubMed PMID: 21844811; PMCID: PMC3661946.

32. Sanders SJ, He X, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE, Murtha MT, Bal VH, Bishop SL, Dong S, Goldberg AP, Jinlu C, Keaney JF, 3rd, Klei L, Mandell JD, Moreno-De-Luca D, Poultney CS, Robinson EB, Smith L, Solli-Nowlan T, Su MY, Teran NA, Walker MF, Werling DM, Beaudet AL, Cantor RM, Fombonne E, Geschwind DH, Grice DE, Lord C, Lowe JK, Mane SM, Martin DM, Morrow EM, Talkowski ME, Sutcliffe JS, Walsh CA, Yu TW, Autism Sequencing C, Ledbetter DH, Martin CL, Cook EH, Buxbaum JD, Daly MJ, Devlin B, Roeder K, State MW. Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. *Neuron*. 2015;87(6):1215-33. Epub 2015/09/25. doi: 10.1016/j.neuron.2015.09.016. PubMed PMID: 26402605.
33. Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC, Sobreira NL, Valle D, Rudd MK, Satten G, Cutler DJ, Pulver AE, Warren ST. Microdeletions of 3q29 confer high risk for schizophrenia. *American journal of human genetics*. 2010;87(2):229-36. Epub 2010/08/10. doi: 10.1016/j.ajhg.2010.07.013. PubMed PMID: 20691406; PMCID: 2917706.
34. Szatkiewicz JP, O'Dushlaine C, Chen G, Chambert K, Moran JL, Neale BM, Fromer M, Ruderfer D, Akterin S, Bergen SE, Kahler A, Magnusson PK, Kim Y, Crowley JJ, Rees E, Kirov G, O'Donovan MC, Owen MJ, Walters J, Scolnick E, Sklar P, Purcell S, Hultman CM, McCarroll SA, Sullivan PF. Copy number variation in schizophrenia in Sweden. *Molecular psychiatry*. 2014;19(7):762-73. Epub 2014/04/30. doi: 10.1038/mp.2014.40. PubMed PMID: 24776740; PMCID: 4271733.
35. Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, Zhang N, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Kendler KS, Freedman R, Dudbridge F, Pe'er I, Hakonarson H, Bergen SE, Fanous AH, Holmans PA, Gejman PV. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *The American journal of psychiatry*. 2011;168(3):302-16. Epub 2011/02/03. doi: 10.1176/appi.ajp.2010.10060876. PubMed PMID: 21285140; PMCID: 4441324.
36. Murphy MM, Lindsey Burrell T, Cubells JF, Espana RA, Gambello MJ, Goines KCB, Klaiman C, Li L, Novacek DM, Papetti A, Sanchez Russo RL, Saulnier CA, Shultz S, Walker E, Mulle JG. Study protocol for The Emory 3q29 Project: evaluation of neurodevelopmental, psychiatric, and medical symptoms in 3q29 deletion syndrome. *BMC Psychiatry*. 2018;18(1):183. Epub 2018/06/10. doi: 10.1186/s12888-018-1760-5. PubMed PMID: 29884173; PMCID: PMC5994080.
37. Hall JG, Allanson JE, Gripp KW, Slavotinek AM. *Handbook of normal physical measurements*. 2nd ed: Oxford University Press; 2006.
38. Elliott CD. *Differential ability scales* (2nd ed.). San Antonio, TX: Harcourt Assessment; 2007.
39. Wechsler D. *Wechsler Abbreviated Scale of Intelligence*. 2nd ed. Bloomington, MN: Pearson; 2011 2011.
40. Sparrow SS, Cicchetti DV, Saulnier CA. *Vineland Adaptive Behavior Scales, Third Edition (Vineland-3)*. San Antonio, TX: Pearson; 2016.
41. Beery KE, Buktenica NA. *The Beery–Buktenica Developmental Test of Visual–Motor Integration: Administration, scoring, and teaching manual* (6th ed.). Minneapolis, MN: Pearson; 2010.
42. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *Journal of autism and developmental disorders*. 1994;24(5):659-85. Epub 1994/10/01. PubMed PMID: 7814313.
43. Lord C, Risi S, Lambrecht L, Cook EH, Jr., Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *Journal of autism and developmental disorders*. 2000;30(3):205-23. Epub 2000/10/31. PubMed PMID: 11055457.
44. Gioia GA, Isquith PK, Guy SC, Kenworthy L. *Behavior rating inventory of executive function*. Odessa, FL: Psychological Assessment Resources, Inc. ; 2000.
45. Silverman W, Albano A. *The Anxiety Disorders Interview Schedule for Children–IV (Child and parent versions)*. San Antonio, TX: Psychological Corporation; 1996.

46. Silverman WK, Saavedra LM, Pina AA. Test-retest reliability of anxiety symptoms and diagnoses with the Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2001;40(8):937-44. Epub 2001/08/15. doi: 10.1097/00004583-200108000-00016. PubMed PMID: 11501694.
47. First MB, Williams JBW, Karg RS, Spitzer RL. User's Guide for the Structured Clinical Interview for DSM-5 Disorders, Research Version (SCID-5-RV). Arlington, VA: American Psychiatric Association; 2015.
48. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. *Journal of the American Academy of Child and Adolescent Psychiatry*. 1997;36(7):980-8. Epub 1997/07/01. doi: 10.1097/00004583-199707000-00021. PubMed PMID: 9204677.
49. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophrenia bulletin*. 2003;29(4):703-15. Epub 2004/03/03. PubMed PMID: 14989408.
50. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. *Schizophrenia bulletin*. 2009;35(5):894-908. Epub 2009/04/24. doi: 10.1093/schbul/sbp027. PubMed PMID: 19386578; PMCID: 2728816.
51. Developmental Disabilities Monitoring Network Surveillance Year Principal I, Centers for Disease C, Prevention. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. *Morbidity and mortality weekly report Surveillance summaries*. 2014;63(2):1-21. Epub 2014/03/29. PubMed PMID: 24670961.
52. Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. *Bull World Health Organ*. 2005;83(7):548-54. Epub 2005/09/24. PubMed PMID: 16175830; PMCID: PMC2626301.
53. Hill DA, Grundmeier RW, Ram G, Spergel JM. The epidemiologic characteristics of healthcare provider-diagnosed eczema, asthma, allergic rhinitis, and food allergy in children: a retrospective cohort study. *BMC Pediatr*. 2016;16:133. Epub 2016/08/21. doi: 10.1186/s12887-016-0673-z. PubMed PMID: 27542726; PMCID: PMC4992234.
54. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. *J Allergy Clin Immunol*. 2010;125(2 Suppl 2):S103-15. Epub 2010/03/05. doi: 10.1016/j.jaci.2009.12.989. PubMed PMID: 20176255.
55. Vasconcelos MMA, East P, Blanco E, Lukacz ES, Caballero G, Lozoff B, Gahagan S. Early Behavioral Risks of Childhood and Adolescent Daytime Urinary Incontinence and Nocturnal Enuresis. *J Dev Behav Pediatr*. 2017;38(9):736-42. Epub 2017/10/19. doi: 10.1097/DBP.0000000000000516. PubMed PMID: 29045258; PMCID: PMC5679404.